Mergers & AcquisitionsBy The Online Investor Staff, updated Sun., Sep. 20, 11:32 PM
|This Slide: #65 of 100|
Slide #65. CryoLife, Inc. — Ascyrus Medical LLC
CryoLife, Inc. (NYSE:CRY)
Ascyrus Medical LLC
CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has acquired Ascyrus Medical LLC (Ascyrus). Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical Dissection Stent (AMDS), the world's first aortic arch remodeling device used for the treatment of acute Type A aortic dissections. The addition of the AMDS to CryoLife's product portfolio further strengthens the Company's position as a leader in the growing aortic repair market.
CryoLife is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Co. has the following product families: BioGlue® Surgical Adhesive products, JOTEC stent grafts and surgical products, On-X mechanical heart valves and surgical products, and implantable cardiac and vascular human tissues. Co.'s medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, and to a lesser extent, other conditions in cardiac and vascular surgery.
CRY SEC Filing Email Alerts Service
Open the CRY Page at The Online Investor »
Buy (3.33 out of 4)
(ranked higher than approx. 56% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite